Probiotics as Adjuvant Therapy May Improve COVID-19 Outcomes

Scientists have discovered that factors such as dysbiosis could influence the SARS-CoV-2 infection course. One can hypothesize that SARS-CoV-2 interacts with the gut microbiota via the gut/lung axis (a cross between the host and all the microbiota sites). With the viral entry into the host cell, leading to lung damage and the subsequent series of reactions that end in an altered expression of antimicrobial peptides on Paneth’s intestinal cells – an alteration that modifies the composition of the intestinal microbiota.

Thus evidently influencing the gut/lung crosstalk. Notably, SARS-CoV-2 infected patients are often administered antibiotics and antivirals, which could also result in further gut microbiota dysbiosis. Based on the study’s rationale, the researchers note it is recommendable to use probiotics, and their metabolites SCFAs (short-chain fatty acids), to reinforce innate and adaptive immunity in SARS-CoV-2 patients. It can be an adjuvant strategy against complications.

The administration of probiotics is observed to increase anti-inflammatory cytokines, decrease proinflammatory cytokines, improve antiviral antibody production, and reduce the viral load. Taking probiotics has immensely improved the condition of the clinical patient, too, in many cases. These observations indicate that the probiotics would be useful in reducing SARS-CoV-2 dissemination in the respiratory tract and gut, reinforcing both anti-inflammatory responses and immune defences.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link: ​http://www.sciencedirect.com/science/article/pii/S187140212030535X

#Featured